Premium
Nefazodone Treatment of Comorbid Alcohol Dependence and Major Depression
Author(s) -
HernandezAvila Carlos A.,
ModestoLowe Vania,
Feinn Richard,
Kranzler Henry R.
Publication year - 2004
Publication title -
alcoholism: clinical and experimental research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.267
H-Index - 153
eISSN - 1530-0277
pISSN - 0145-6008
DOI - 10.1097/01.alc.0000118313.63897.ee
Subject(s) - nefazodone , placebo , anxiety , psychology , depression (economics) , psychiatry , medicine , serotonin , receptor , alternative medicine , pathology , economics , fluoxetine , macroeconomics
A bstract : Background: Major depression is a common comorbid condition among individuals with alcohol dependence. This study examined the effects of nefazodone, a norepinephrine and serotonin reuptake blocker and 5‐hydroxytryptamine‐2 receptor antagonist, on mood and anxiety symptoms and drinking behavior in a sample of depressed alcoholics. Methods: This study was a double‐blind, placebo‐controlled comparison of nefazodone (200–600 mg/day) or placebo in a sample of alcohol‐dependent subjects ( n = 41; 52% women) with current major depression. After a 1‐week placebo lead‐in period, subjects were randomly assigned to receive study medication and supportive psychotherapy for 10 weeks. Results: Depressive and anxiety symptoms declined significantly over time. Although the nefazodone group showed greater reductions in these symptoms, the effects did not reach statistical significance. Nonetheless, nefazodone‐treated subjects showed a significantly greater reduction in heavy drinking days and in total drinks compared with placebo‐treated subjects. Conclusions: The lack of significant effects on depression and anxiety symptoms may reflect limited statistical power. Despite the small sample size, nefazodone significantly reduced some measures of alcohol consumption in this sample of depressed alcoholics.